OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC

May 21st 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

Dr. Nye on Neratinib-Associated Diarrhea in HER2+ Breast Cancer

May 21st 2019

Lauren Nye, MD, assistant professor, University of Kansas Medical Center, discusses the concern of neratinib-associated diarrhea in patients with HER2-positive breast cancer.

Dr. Oaknin Discusses Findings of the GARNET Study in Endometrial Cancer

May 20th 2019

Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses findings of the GARNET study in endometrial cancer.

Dr. Philip Discusses Research Questions With Lutathera in NETs

May 20th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Barbara Ann Karmanos Cancer Institute, discusses research questions with Lutathera in the treatment of patients with neuroendocrine tumors.

Dr. Nadler on the Impact of Immunotherapy in Squamous NSCLC

May 20th 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

Dr. Brander on Targeted Agents in CLL

May 18th 2019

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses targeted agents in chronic lymphocytic leukemia (CLL).

Dr. Konner on Preferred Platinum Doublets in Recurrent Ovarian Cancer

May 18th 2019

Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.

Dr. Shields on the Standard of Care in Newly Diagnosed mCRC

May 18th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Dr. Daud Discusses the Immunogenicity of Melanoma

May 17th 2019

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.

Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

May 17th 2019

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

The Significance of JTCC Joining Georgetown Lombardi Cancer Consortium

May 17th 2019

Robert C. Garrett, FACHE, chief executive officer, Hackensack Meridian Health, discusses the significance of John Theurer Cancer Center joining the Georgetown Lombardi Cancer Consortium.

Dr. Agarwal on Patient Selection in Frontline Advanced RCC

May 17th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses patient selection in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Dr. Sonpavde on Key Data With Immunotherapy in Metastatic Bladder Cancer

May 17th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses key data with immunotherapy in metastatic bladder cancer.

Dr. Navai on Treatment Options in Relapsed/Refractory Sarcoma

May 17th 2019

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

Dr. Khan Discusses Sequencing Strategies in Advanced HCC

May 17th 2019

Gazala N. Khan, MD, gastrointestinal medical oncologist, Henry Ford Health System, discusses sequencing strategies in advanced hepatocellular carcinoma.

Dr. Banna on the Potential for CAR T-Cell Therapy in Lung Cancer

May 17th 2019

Giuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.

Dr. Hong on the Safety Profile of Tisotumab Vedotin in Cervical Cancer

May 16th 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Dr. Musher on Investigational Combination Therapies in HCC

May 16th 2019

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses emerging combination therapies in hepatocellular carcinoma (HCC).

Dr. McGregor on the Utility of Axitinib/Avelumab in Advanced RCC

May 16th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the data with the combination of axitinib (Inlyta) and avelumab (Bavencio) in advanced renal cell carcinoma (RCC).

Dr. Langer Discusses the Impact of Targeted Therapy in NSCLC

May 15th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of targeted therapy in non–small cell lung cancer.